BioSpace News Archive

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibodi Hospital, Faculty of Medicine, Mahidol University (TH001) in Thailand was successfully conducted on March 22, 2023.

Innate Pharma SA announced the filing of its 2022 Universal Registration Document for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” on April 6, 2023.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the Annual Report for 2022 has been published.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, will present new data supporting GJB2-GT program candidate selection to address hearing loss related to mutations in the GJB2 gene during the Company’s R&D Day taking place , Thursday, April 6, 2023.

Avacta Group plc announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.The two sites, Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolment to ALS-6000-101.

Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Sensible Biotechnologies, Inc., an mRNA platform company, has announced a $4.2mn pre-seed round to accelerate the development of its cell-based platform for cost-efficient manufacturing of high-quality mRNA.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX‑629, an investigational new drug, for the treatment of atopic dermatitis.

Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced changes to its leadership team.